Dr. Weckbaugh on the LIBRETTO-001 Trial in NSCLC

Brandon Weckbaugh, MD
Published: Wednesday, Apr 03, 2019



Brandon Weckbaugh, MD, an oncology fellow at the University of Missouri-Kansas City, discusses the results of the LIBRETTO-001 trial in the patients with non–small cell small cancer (NSCLC).

The LIBRETTO-001 trial (NCT03157128) is a phase I/II trial investigating LOXO-292 in patients with advanced solid tumors, RET fusion–positive solid tumors, and medullary thyroid cancer. LOXO-292 is a TKI targeting the RET mutation. Data from the trial showed some encouraging responses in patients with RET fusion mutation-driven cancers, irrespective of the RET fusion partner, as well as prior kinase inhibitor therapy, says Weckbaugh.

In September 2018, the FDA granted LOXO-292 a breakthrough therapy designation for the treatment of patients with RET fusion–positive NSCLC or RET-mutant medullary thyroid cancer. The breakthrough therapy designation is specific to patients with metastatic RET fusion-positive NSCLC who require systemic therapy and have progressed following platinum-based chemotherapy and an anti–PD-1 or anti–PD-L1 therapy.
SELECTED
LANGUAGE


Brandon Weckbaugh, MD, an oncology fellow at the University of Missouri-Kansas City, discusses the results of the LIBRETTO-001 trial in the patients with non–small cell small cancer (NSCLC).

The LIBRETTO-001 trial (NCT03157128) is a phase I/II trial investigating LOXO-292 in patients with advanced solid tumors, RET fusion–positive solid tumors, and medullary thyroid cancer. LOXO-292 is a TKI targeting the RET mutation. Data from the trial showed some encouraging responses in patients with RET fusion mutation-driven cancers, irrespective of the RET fusion partner, as well as prior kinase inhibitor therapy, says Weckbaugh.

In September 2018, the FDA granted LOXO-292 a breakthrough therapy designation for the treatment of patients with RET fusion–positive NSCLC or RET-mutant medullary thyroid cancer. The breakthrough therapy designation is specific to patients with metastatic RET fusion-positive NSCLC who require systemic therapy and have progressed following platinum-based chemotherapy and an anti–PD-1 or anti–PD-L1 therapy.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x